Lam Cindy, Landry Sébastien, Moussa Ghina, Sakr Dania, Varinot Gabriel, Mousseau Katherine, Martel Dominic, Frenette Anne Julie, Ambaraghassi Georges, Rouleau Danielle, Cantarovich Marcelo, Klein Marina B, Sheehan Nancy L, Lemire Benoît
Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.
Department of Pharmacy, McGill University Health Centre (MUHC), Montréal, QC, Canada.
Transplant Direct. 2023 Jan 26;9(2):e1441. doi: 10.1097/TXD.0000000000001441. eCollection 2023 Feb.
The pharmacotherapeutic management of people living with HIV (PLWHIV) undergoing solid organ transplantation (SOT) is clinically challenging, mainly due to the frequent occurrence of complex drug-drug interactions. Although various strategies have been proposed to improve treatment outcomes in these patients, several uncertainties remain, and consensus practice guidelines are just beginning to emerge. The main objective of this scoping review was to map the extent of the literature on the pharmacotherapeutic interventions performed by healthcare professionals for PLWHIV undergoing SOT.
We searched Medline, Embase, and the Cochrane databases as well as gray literature for articles published between January 2010 and February 2020. Study selection was performed by at least 2 independent reviewers. Articles describing pharmacotherapeutic interventions in PLWHIV considered for or undergoing SOT were included in the study.
Of the 12 599 references identified through our search strategy, 209 articles met the inclusion criteria. Results showed that the vast majority of reported pharmacotherapeutic interventions concerned the management of immunosuppressive and antimicrobial therapy, including antiretrovirals. Analysis of the data demonstrated that for several aspects of the pharmacotherapeutic management of PLWHIV undergoing SOT, there were differing practices, such as the choice of immunosuppressive induction and maintenance therapy. Other important aspects of patient management, such as patient counseling, were rarely reported.
Our results constitute an extensive overview of current practices in the pharmacotherapeutic management of SOT in PLWHIV and identify knowledge gaps that should be addressed to help improve patient care in this specific population.
对接受实体器官移植(SOT)的艾滋病毒感染者(PLWHIV)进行药物治疗管理在临床上具有挑战性,主要是因为频繁出现复杂的药物相互作用。尽管已经提出了各种策略来改善这些患者的治疗效果,但仍存在一些不确定性,并且共识性实践指南才刚刚开始出现。本范围综述的主要目的是梳理医疗保健专业人员对接受SOT的PLWHIV进行药物治疗干预的文献范围。
我们检索了Medline、Embase和Cochrane数据库以及灰色文献,以查找2010年1月至2020年2月期间发表的文章。研究选择由至少2名独立评审员进行。纳入研究的文章描述了针对考虑进行或正在接受SOT的PLWHIV的药物治疗干预。
通过我们的检索策略识别出的12599篇参考文献中,209篇文章符合纳入标准。结果表明,绝大多数报告的药物治疗干预涉及免疫抑制和抗菌治疗的管理,包括抗逆转录病毒药物。数据分析表明,对于接受SOT的PLWHIV药物治疗管理的几个方面,存在不同的做法,例如免疫抑制诱导和维持治疗的选择。患者管理的其他重要方面,如患者咨询,很少被报道。
我们的结果全面概述了目前对接受SOT的PLWHIV进行药物治疗管理的实践,并确定了为帮助改善这一特定人群的患者护理而应解决的知识空白。